

NCRO HIGHLIGHTS

Duke
Neuroscience

Neuroscience Clinical Research Organization

Division of Neurology
Department of Medicine
Duke University Health System



May 2005

The mission of the NCRO is to foster the development of a world-class neuroscience clinical trials center.

Who's Who in the NCRO

Management

Carmelo Graffagnino, Medical Director
Mark Stacy, Director of Operations
Ron Beauvais, Administrator
Donna Carnes, Regulatory Assistant
Sharon Dowell, Administrative Manager
Lisa Gauger, Clinical Research Administrator
JoAnn Jones, Regulatory Administrator

Coordination

Kate Beck 668-2278
Gail Cook 684-0865
Joanne Field 668-2842
Karen Grace 668-2844
Debra Heydt 668-2843
Rene Link 970-1648
Sarah Wyne 668-2837

Email:

beck0002@mc.duke.edu
cook0007@mc.duke.edu
joanne.field@duke.edu
karen.grace@duke.edu
debra.heydt@duke.edu
link0002@mc.duke.edu
wyn0001@mc.duke.edu

Please join us in welcoming Karen Grace as the newest addition to our clinical research coordinator team. We're excited to welcome her aboard!

****STUDY SPOTLIGHT****

New Approved Study Ready for Recruitment!!

If you have patients who may be interested in participating in the below-referenced study, please contact the individuals listed below – Thank you for your Support!

B. Scott (PI) – National Institute of Neurological Disorders and Stroke (NINDS)

“Parkinson’s Disease Care-Seeking Motivations and Attendant Issues: A Proposed Qualitative Study of Patients, Intimates of Patients, and Target Audiences.”

The purpose of this study is to achieve an objective understanding of the following two questions: 1) What factors are operative as treatment-seeking barriers among minority adults with possible Parkinson’s disease (PD) symptoms? and 2) What are the barriers and incentives for enrolling in clinical trials among minority adults currently being treated for PD? Potential patient participants in focus groups will be approached by the site physician or nurse. Only if they agree to participate will their contact information be given to the interviewer. Patients will be given a form to pass on to one intimate that lists the date, time and location of the focus group for intimates. Focus groups will consist of minority PD patients who have been in long-duration care, defined as >5 years from diagnosis; minority PD patients who have been in short-duration PD care, defined as <5 years from diagnosis; caucasian PD patients; intimates of current minority PD patients; and 15 one-on-one interviews with minority adults (55 years of age or older) who are not currently being treated for PD or any other condition with PD-like symptomatology. We estimate to enroll up to 55 subjects here at Duke. Contact Burt Scott or Lisa Gauger (668-1538) if you have a patient who may be interested in participating in this study.

We would like your suggestions for topics in future issues of the NCRO Newsletter! Please send your suggestions to: JoAnn Jones @ jones018@mc.duke.edu.

ACTIVE ENROLLING STUDIES

The NCRO currently supports **41** active studies. This list includes only those studies that are actively enrolling. Please help us reach our targets (column 6).

DEMENTIA STUDIES

PI	SPONSOR	INDICATION	STUDY-ID	COORDINATOR	TARGET / # PTS ENROLLED-5/31/05
BURKE, Jim	GlaxoSmithKline	Mild to Moderate AD	Rosiglitazone XR	Heydt 668-2843	15 / 4
WHITE, Heidi	NIH	Mild cog. Impairment	Nicotine Tr of MCI	Cook 684-0865	25 / 8

EPILEPSY

HUSAIN, Aatif	Schwarz	Epilepsy-partial seizures	SPM 927 (SP 754)	Beck 668-2278	5 / 4
---------------	---------	---------------------------	------------------	---------------	-------

GENERAL

Hurwitz, Barrie	Berlex	RR-Multiple Sclerosis	Beyond	Wyne 668-2837	15 / 12
-----------------	--------	-----------------------	--------	---------------	---------

MOVEMENT DISORDERS

MORGENLANDER, J	Private Investors	Restless Legs	RLS	N/A	20 / 6
SCOTT, Burt	Physician Funded	Movement disorder	Visual Documentation	N/A	No Target / 464
SCOTT, Burt	Physician Funded	Movement disorder	Tetrabenazine	N/A	No Target / 54
SCOTT, Burt	Wyeth Pharm	PD-ERT	POETRY	Gauger 668-1538	5 / 2
SCOTT, Burt	Kyowa	PD-motor response complications	KW-6002 (6002-US-018)	Cook 684-0865	8 / 7
SCOTT, Burt	Boston Life Sciences	Altropane	PD – tremors	Wyne 668-2837	20 / 2
SCOTT, Burt	NINDS	Minority qualitative study	PD – care-seeking motivations/attendant issues	Gauger 668-1538	55 / 0
STACY, Mark	Novartis	PD requiring levodopa	Stride PD (Stalevo)	Beck 668-2278	10 / 10
STACY, Mark	Inst Neurodeg Disorder	Early PD	SPECT imaging	Gauger 668-1538	8 / 1
STACY, Mark	Merck KgaA	PD with tx dyskinesias	Sarizotan	Gauger 668-1538	12 / 8

NEUROMUSCULAR

BEDLACK, Rick	Columbia / NINDS	ALS	Minocycline	Grace 668-2844	15-20 / 6
BEDLACK, Rick	Dainippon AS-3201-253	Diabetic sensorimotor polyneuropathy	AS-3201	Grace 668-2844	20 / 3
MASSEY, Janice	Hoffman LaRoche-Aspreva	Myasthenia Gravis	Mycophenolate mofetil	Provided by Physician	6 / 0
MASSEY, Janice	FDA	Myasthenia Gravis	MG-Cellcept	Provided by Physician	10 / 9

VASCULAR

GOLDSTEIN, Larry	AGA Med Corp	Cryptogenic stroke	RESPECT	Link 970-1648	10 / 12
GOLDSTEIN, Larry	Boehringer Ingelheim	Recurrent strokes	PRoFESS	Link 970-1648	30 / 10
GRAFFAGNINO, C	NIH / Wash Univ	Carotid occlusion	Surgery vs stan med care	Stoner 668-5275	30 / 0
GRAFFAGNINO, C	AstraZeneca-	Acute ischemic stroke	Stroke-SA-NXY-0007	Stoner 668-5275	10 / 9
GRAFFAGNINO, C	Centocor	Acute ischemic stroke	AbESTT II	Stoner 668-5275	12 / 1
GRAFFAGNINO, C	AstraZeneca	Acute ICH	CHANT-SA-NXY-0012	Stoner 668-5275	3-6 / 1
LASKOWITZ, Danny	Biosite	Biomarker-brain injury	Triage Stoke Panel	B. Blessing 970-4888	450 / 491
LASKOWITZ, Danny	Merck & Phys Funded	Aneurismal SAH	Simvastatin-SAH	B. Blessing 970-4888	120 / 45
LYNCH, John	Physician Funded	Traumatic brain injury	Simvastatin-TBI	B. Blessing 970-4888	100 / 6

**CTQA LUNCH AND LEARN SERIES
2004-2005 Schedule**

The lunch and learn series are one hour **coordinator centric educational sessions** with the primary goal of providing useful, hands on knowledge to build a stronger research work force. These sessions will also provide the members of the CTQA office an opportunity to present themselves as a resource to the research community.

Look for the updated CTQA schedule in an upcoming issue of the Newsletter once the CTQA Office finalizes the dates.

ALL SESSIONS ARE FROM 12:00-1:00pm AND HELD IN ROOM 103 BRYAN RESEARCH BUILDING. SEATING IS ON A FIRST COME, FIRST SERVED BASIS FOR THOSE WHO HAVE REGISTERED FOR THE SERIES.

**PLEASE REGISTER FOR THE SERIES BY E-MAILING CTQA@MC.DUKE.EDU
BRING YOUR LUNCH. THE COMPLIANCE OFFICE WILL PROVIDE DRINKS AND DESSERTS!!**